ReviewDiscover oncology2026
KLRB1 gene in tumor immune regulation and disease prognosis: a multidimensional role review.
Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The CD161 protein encoded by the killer cell lectin-like receptor subfamily B member 1 (KLRB1) gene is a key immunoregulatory molecule, primarily expressed in natural killer (NK) cells and specific T cell subsets, playing a significant role in tumors and various immune-related diseases. With the application of multi-omics big data and single-cell sequencing technologies, the mechanisms by which KLRB1 functions in tumorigenesis, progression, and immune microenvironment regulation are becoming increasingly clear. This paper elucidates the mechanism by which KLRB1 mediates immune activation and immune evasion through the regulation of downstream signaling pathways, its multifaceted roles within the tumor microenvironment (TME), and explores its function in immunotherapy. This article systematically reviews the expression characteristics of KLRB1 in various cancers such as breast cancer, hepatocellular carcinoma, and colorectal cancer, and analyzes the correlation between its expression levels and patient prognosis as well as immune cell infiltration in the TME. Beyond the field of oncology, the important role of KLRB1 in other immune-related diseases such as sepsis, psoriasis, and osteoporosis is also increasingly prominent. In-depth research on KLRB1 will provide new insights for future diagnostic and therapeutic strategies for the aforementioned diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.